The immunological efficacy of the Russia-developed coronavirus vaccine EpiVacCorona is 100 per cent, the Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being said on Tuesday.
The immunological efficacy of the Russia-developed coronavirus vaccine EpiVacCorona is 100 per cent, Sputnik News quoted the Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being as saying.
EpiVacCorona is a coronavirus vaccine developed by the Vektor State Research Center of Virology and Biotechnology in Russia.
The mass trials of EpiVacCorona has begun in Russia in November. The peptide-based vaccine is the second to be licensed for use in Russia.
Moscow has said its other approved Covid-19 vaccine, Sputnik V, is 92 per cent effective at protecting people from Covid-19 according to interim results.
Russia on Tuesday said that its second Covid-19 vaccine manufactured by Vector Institute has shown 100% efficacy. The announcement is based on results of clinical trials, reported Reuters quoting news agency TASS.
Russia began mass trials of EpiVacCorona, which is being developed by Siberia's Vector Institute, in November.
Mass production of the country's second Covid vaccine, will be launched in February 2021, Russian Deputy Prime Minister Tatiana Golikova said on Monday, reported TASS.
"We will begin mass production of the Epivaccorona vaccine developed by the Vector Center in February 2021," she said.
On July, 24, 2020, the Vector State Research Center of Virology and Biotechnology received a Russian health ministry permit for clinical trials of its anti-coronavirus vaccine on volunteers. The first volunteer was inoculated on July 27. The vaccine’s clinical trials were completed on September 30.